Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: Long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)

Blood

Volumn 111, Issue 1, 2008, Pages 109-111

  Schulz, Holger ^a   Rehwald, Ute ^a   Morschhauser, Franck ^b   Elter, Thomas ^a   Driessen, Christoph ^c   Rüdiger, Thomas ^d   Borchmann, Peter ^a   Schnell, Roland ^a   Diehl, Volker ^a   Engert, Andreas ^a   Reiser, Marcel ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; RITUXIMAB;

ADULT; ANTIGEN EXPRESSION; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GERMANY; HODGKIN DISEASE; HUMAN; LYMPHOCYTE; MALE; MULTICENTER STUDY; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLENECTOMY;

EID: 38049162295     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-078725     Document Type: Article

References (17)

1. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol. 1999;17:776-783.
2. Jaffe ES, Harris NL, Stein H, Vardiman JW. WHO Classification of Tumours Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
3. Rüdiger T, Gascoyne RD, Jaffe ES, de Jong D. Worhshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyte-rich B cell lymphoma. Ann Oncol. 2002;13 Suppl 1:44-51.
4. Lukes RJ, Butler J, Hicks EB. [The prognosis of Hodgkin's disease according to the histologic type and the clinical stage. Role of the reactions of the host]. Nouv Rev Fr Hematol. 1966;6:15-22.
5. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer. 1983;51:2293-2300.
6. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood. 2003;101:420-424.
7. Cosset JM, Henry-Amar M, Meerwaldt JH. Longterm toxicity of early stages of Hodgkin's disease therapy: the EORTC experience. EORTC Lymphoma Cooperative Group. Ann Oncol. 1991;2 Suppl 2:77-82.
8. Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al. Lymphocyte- predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection-a Study of the French Society of Pediatric Oncology. J Clin Oncol. 2003;21:2948-2952.
9. Wirth A, Yuen K, Barton M, et al. Long-term outcome after radiotherapy alone for lymphocytepredominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group. Cancer. 2005;104:1221-1229.
10. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101:4285-4289.
11. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96:1889-1899.
12. Nogova L, Reineke T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma-comparison of outcomes. Eur J Haematol Suppl. 2005;75:106-110.
13. Younes A, Fayad LY, Goy A, et al. Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: improvement of event free survival (EFS) in all international prognostic score (IPS) groups [abstract]. Blood. 2006;108:2742.
14. Hansmann ML, Stein H, Fellbaum C, Hui PK, Parwaresch MR, Lennert K. Nodular paragranuloma can transform into high-grade malignant lymphoma of B type. Hum Pathol. 1989;20:1169-1175.
15. Boudová L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102:3753-3758.
16. Delabie J, Vandenberghe E, Kennes C, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol. 1992;16:37-48.
17. McBride JA, Rodriguez J, Luthra R, Ordonez NG, Cabanillas F, Pugh WC. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol. 1996;20:193-201.